| CHINESE | JAPANESE | KOREAN |
  Home         Investment Guide          News          Special Coverage          News in Retrospect          Contact Us
  Industries & Enterprises  | Tourism & Leisure  | Education & Schools  | Infrastructure & Ecology  | Life & Culture  | Authorities & Policies
 
  See you by Dushu Lake!...
180.jpg
 
  7th Jinji Lake Double ...
181.png
 
  Merry Christmas Eve an...
圣诞专题-03.png
 
  5th "Sungent Cup" Suzh...
宽2.jpg
 
  Suzhou Ballet Theatre ...
芭蕾舞1.jpg
 
 
Current Position: Home page > category report > Industries & Enterprises
  Print page Text size:  
 


Yu Dechao awarded science innovator 2016


According to CCTV, the recording of The Award Ceremony of Science Innovators 2016 was finished recently.

As revealed, 10 individuals and 3 teams were awarded the title of Science Innovator/Team 2016. Dr. Yu Dechao (Michael Yu), an expert in the “1,000 Talents Program”, and founder and chairman of Innovent Biologics, Inc., in Suzhou, won the honor.

Yu at CCTV’s The Award Ceremony of Science Innovators 2016

The award is known as one of the heavyweight science and technology awards. The Nobel Laureate Tu Youyou won the title in 2015. This yearis appraisal was co-organized by 8  organizations including CCTV, Chinese Academy of Sciences, Ministry of Science and Technology, Ministry of Education and Chinese Academy of Engineering. It is aimed at honoring scientific and technological personnel who have made significant contributions in areas that follow the latest international development and serve China’s major economic needs.

Yu got his doctoral degree from Chinese Academy of Sciences and went to University of California in 1993 to do his postdoctoral research in pharmaceutical chemistry. After that, he continued his bio-medicine research in America. In 2006, he returned to China to start his own business and founded Innovent Biologics, Inc. in SIP in 2011. 

Over the past five years, Innovent Biologics has developed very fast, making new records in China’s biopharmaceutical industry one after another. In 2015, Innovent signed two comprehensive cooperation agreements with Eli Lilly, yielding an investment of about $3.3 billion. In 2016, Innovent finished series D fundraising worth $260 million, a record high in the history of fundraising in China’s pharmaceutical sector and the second largest worldwide in 2016.

The judging panel believed that Innovent’s international cooperation and fundraising were meaningful like a “wind indicator”, showing the world the power of China’s biopharmaceutical industry and setting a new pattern of using global capital to drive R&D.

Source:Suzhou Daily
January 19, 2017

 
 
   
 
  FEATURED VIDEOS  
     
   
  Suzhou Industrial Park Video  
  Watch